Jianzhong Zhang
Research Subjects
Jianzhong Zhang has a total of 31 co-authors. Here are the top co-authors by number of shared publications:
Bo Tian
Department of Intensive Care Unit, Shanghai East Hospital, Tongji University, Shanghai 200120, China
1 shared publicationChengwei Chen
Liver Disease Center of Naval 905 Hospital, Shanghai, China
1 shared publicationFujian Li
Division of Tuberculosis, Zhejiang Hospital of Integrated Traditional Chinese and Western Medicine, Hangzhou, China
1 shared publication- Hai Gao
Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University and National Clinical Research Center for Cardiovascular Diseases, Beijing, China
1 shared publication Haijun Zhong
Division of Tumor, Zhejiang Provincial Tumor Hospital, Hangzhou, China
1 shared publicationHan Lin
Digestive Endoscopy Center, Department of Gastroenterology, Changhai Hospital, Naval Medical University, Shanghai 200433, China
1 shared publication
Latest Publications
- Open Access
- 16 September 2026
- Published by Elsevier in SSRN Electronic Journal
A Comparative Analysis of Academic Clinical Studies in China and the United States, 2010-2024
Background: Academic clinical studies are essential for addressing unmet medical needs. China and the US are two major contributors to global clinical research. We aimed to assess to what extent academic clinical studies in China have converged with those in the US.Methods: In this registry-based study, we included academic clinical studies, defined as studies without industry funding, initiated from 2010 to 2024, registered in ClinicalTrials.gov or the ChiCTR, with principal investigators based in mainland China or the US. We compared volume, study characteristics and leading disease areas. Publication outcomes were tracked through 2025 and restricted to the ClinicalTrials.gov subset, which provides systematically study-to-publication linkage. Outcomes included time to first publication, 5-year publication output, and journal impact metrics.Findings:96 632 US-initiated and 120 712 China-initiated academic clinical studies were included. Annual initiation expanded rapidly in China (average annual percent change [AAPC], 23.61%; 95% CI, 22.80%-24.39%; P < .001), surpassing the US in 2018, whereas the US grew modestly (AAPC, 2.75%; 2.40%-3.10%; P < .001). International studies remained rare in China (peaking at 0.65% in 2011) versus the US (5.26% to 6.65%). China emphasized somatic diseases; the US emphasized mental and neurological disorders. The probability of at least one publication was similar (China: 29.84% vs US: 29.53%; log-rank P = .530), but 5-year publication output per study was lower in China in most years since 2014 (rate ratios, 0.75 to 0.89). China exceeded the US in median journal impact factor since 2019 (2020 cohort, 4.20 vs 3.50, adjusted P < .001). The proportion of publications in The Lancet, the New England Journal of Medicine, JAMA, or The BMJ did not differ significantly in any initiation-year cohort (2020 cohort, 13 of 667 publications [1.95%] in China vs 39 of 1936 publications [2.01%] in US; adjusted P = 1.000).Interpretation: China achieved substantial gains in the scale and journal-level impact of academic clinical studies. The US remained ahead in international collaboration and per-study publication yield. These complementary strengths highlight the potential value of China-US collaboration for global clinical research.
- 16 September 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessA Comparative Analysis of Academic Clinical Studies in China and the United States, 2010-2024
Background: Academic clinical studies are essential for addressing unmet medical needs. China and the US are two major contributors to global clinical research. We aimed to assess to what extent academic clinical studies in China have converged with those in the US.Methods: In this registry-based study, we included academic clinical studies, defined as studies without industry funding, initiated from 2010 to 2024, registered in ClinicalTrials.gov or the ChiCTR, with principal investigators based in mainland China or the US. We compared volume, study characteristics and leading disease areas. Publication outcomes were tracked through 2025 and restricted to the ClinicalTrials.gov subset, which provides systematically study-to-publication linkage. Outcomes included time to first publication, 5-year publication output, and journal impact metrics.Findings:96 632 US-initiated and 120 712 China-initiated academic clinical studies were included. Annual initiation expanded rapidly in China (average annual percent change [AAPC], 23.61%; 95% CI, 22.80%-24.39%; P < .001), surpassing the US in 2018, whereas the US grew modestly (AAPC, 2.75%; 2.40%-3.10%; P < .001). International studies remained rare in China (peaking at 0.65% in 2011) versus the US (5.26% to 6.65%). China emphasized somatic diseases; the US emphasized mental and neurological disorders. The probability of at least one publication was similar (China: 29.84% vs US: 29.53%; log-rank P = .530), but 5-year publication output per study was lower in China in most years since 2014 (rate ratios, 0.75 to 0.89). China exceeded the US in median journal impact factor since 2019 (2020 cohort, 4.20 vs 3.50, adjusted P < .001). The proportion of publications in The Lancet, the New England Journal of Medicine, JAMA, or The BMJ did not differ significantly in any initiation-year cohort (2020 cohort, 13 of 667 publications [1.95%] in China vs 39 of 1936 publications [2.01%] in US; adjusted P = 1.000).Interpretation: China achieved substantial gains in the scale and journal-level impact of academic clinical studies. The US remained ahead in international collaboration and per-study publication yield. These complementary strengths highlight the potential value of China-US collaboration for global clinical research.
- 4 August 2019
- Published by Wiley in Liver International
- Vol. 39 (11) , 2102-2111
Efficacy and safety of magnesium isoglycyrrhizinate injection in patients with acute drug‐induced liver injury: A phase II trial
Background: Drug‐induced liver injury (DILI) is the most common reason for a drug to be withdrawn from the market. Apart from stopping the offending drug, no regimens are available for treating idiosyncratic DILI in clinical practice.Methods: We carried out a randomized, double‐blind, multidoses, active drug controlled, multicentre phase II trial to assess the safety and efficacy of the study drug, magnesium isoglycyrrhizinate (MgIG), as compared to tiopronin, a standard therapy for DILI in China. The primary outcome was the proportion of alanine aminotransferase (ALT) normalization at week 4 after study drug administration. Logistic regression was used to examine the odds of ALT normalization between low dose (Group A) and high dose (Group B) vs active control (Group C).Results: One hundred and seventy‐four eligible subjects were randomized and enrolled into three groups: 59 in group A, 56 in group B and 59 in group C. It was shown that group A and group B lowered ALT level even at early stage of study drug administration; when compared with Group C (61.02%), the proportions of ALT normalization at week 4 were significantly greater in Group A (84.75%, P = .0029) and Group B (85.71%, P = .0037) respectively. The results from the univariate logistic model showed that the odds of ALT normalized among subjects in Group A were about 3.6 times greater (OR = 3.55, 95% CI: 1.47‐8.57, P = .0049) than subjects in Group C. Similar effect was observed among subjects in Group B (OR = 3.83, 95% CI: 1.54‐9.55, P = .0039).Conclusions: This trial provided preliminary evidence that MgIG is an effective and safe treatment for patients with acute DILI.
- 4 August 2019
- Published by Wiley in Liver International
- Vol. 39 (11) , 2102-2111
Efficacy and safety of magnesium isoglycyrrhizinate injection in patients with acute drug‐induced liver injury: A phase II trial
Background: Drug‐induced liver injury (DILI) is the most common reason for a drug to be withdrawn from the market. Apart from stopping the offending drug, no regimens are available for treating idiosyncratic DILI in clinical practice.Methods: We carried out a randomized, double‐blind, multidoses, active drug controlled, multicentre phase II trial to assess the safety and efficacy of the study drug, magnesium isoglycyrrhizinate (MgIG), as compared to tiopronin, a standard therapy for DILI in China. The primary outcome was the proportion of alanine aminotransferase (ALT) normalization at week 4 after study drug administration. Logistic regression was used to examine the odds of ALT normalization between low dose (Group A) and high dose (Group B) vs active control (Group C).Results: One hundred and seventy‐four eligible subjects were randomized and enrolled into three groups: 59 in group A, 56 in group B and 59 in group C. It was shown that group A and group B lowered ALT level even at early stage of study drug administration; when compared with Group C (61.02%), the proportions of ALT normalization at week 4 were significantly greater in Group A (84.75%, P = .0029) and Group B (85.71%, P = .0037) respectively. The results from the univariate logistic model showed that the odds of ALT normalized among subjects in Group A were about 3.6 times greater (OR = 3.55, 95% CI: 1.47‐8.57, P = .0049) than subjects in Group C. Similar effect was observed among subjects in Group B (OR = 3.83, 95% CI: 1.54‐9.55, P = .0039).Conclusions: This trial provided preliminary evidence that MgIG is an effective and safe treatment for patients with acute DILI.
- Open Access
- 28 February 2019
- Published by Baishideng Publishing Group Inc. in World Journal of Gastroenterology
- Vol. 25 (8) , 1024-1030
Establishing a model to measure and predict the quality of gastrointestinal endoscopy
BACKGROUND Tens of millions of gastrointestinal endoscopic procedures are performed every year in China, but the quality varies significantly and related factors are complex. Individual endoscopist- and endoscopy division-related factors may be useful to establish a model to measure and predict the quality of endoscopy. AIM To establish a model to measure and predict the quality of gastrointestinal endoscopic procedures in mainland China. METHODS Selected data on endoscopy experience, equipment, facility, qualification of endoscopists, and other relevant variables were collected from the National Database of Digestive Endoscopy of China. The multivariable logistic regression analysis was used to identify the potential predictive variables for occurrence of medical malpractice and patient disturbance. Linear and nonlinear regressions were used to establish models to predict incidence of endoscopic complications. RESULTS In 2012, gastroscopy/colonoscopy-related complications in mainland China included bleeding in 4,359 cases (0.02%) and perforation in 914 (0.003%). Endoscopic-retrograde-cholangiopancreatography-related complications included severe acute pancreatitis in 593 cases (0.3%), bleeding in 2,151 (1.10%), perforation in 257 (0.13%) and biliary infection in 4,125 (2.11%). Moreover, 1,313 (5.0%) endoscopists encountered with medical malpractice, and 5,243 (20.0%) encountered with the disturbance from patients. The length of endoscopy experience, weekly working hours, weekly night shifts, annual vacation days and job satisfaction were predictors for the occurrence of medical malpractice and patient disturbance. However, the length of endoscopy experience and the ratio of endoscopists to nurses were not adequate to establish an effective predictive model for endoscopy complications. CONCLUSION The workload and job satisfaction of endoscopists are valuable predictors for medical malpractice or patient disturbance. More comprehensive data are needed to establish quality-predictive models for endoscopic complications.
- 28 February 2019
- Published by Baishideng Publishing Group Inc. in World Journal of Gastroenterology
- Vol. 25 (8) , 1024-1030
Open AccessEstablishing a model to measure and predict the quality of gastrointestinal endoscopy
BACKGROUND Tens of millions of gastrointestinal endoscopic procedures are performed every year in China, but the quality varies significantly and related factors are complex. Individual endoscopist- and endoscopy division-related factors may be useful to establish a model to measure and predict the quality of endoscopy. AIM To establish a model to measure and predict the quality of gastrointestinal endoscopic procedures in mainland China. METHODS Selected data on endoscopy experience, equipment, facility, qualification of endoscopists, and other relevant variables were collected from the National Database of Digestive Endoscopy of China. The multivariable logistic regression analysis was used to identify the potential predictive variables for occurrence of medical malpractice and patient disturbance. Linear and nonlinear regressions were used to establish models to predict incidence of endoscopic complications. RESULTS In 2012, gastroscopy/colonoscopy-related complications in mainland China included bleeding in 4,359 cases (0.02%) and perforation in 914 (0.003%). Endoscopic-retrograde-cholangiopancreatography-related complications included severe acute pancreatitis in 593 cases (0.3%), bleeding in 2,151 (1.10%), perforation in 257 (0.13%) and biliary infection in 4,125 (2.11%). Moreover, 1,313 (5.0%) endoscopists encountered with medical malpractice, and 5,243 (20.0%) encountered with the disturbance from patients. The length of endoscopy experience, weekly working hours, weekly night shifts, annual vacation days and job satisfaction were predictors for the occurrence of medical malpractice and patient disturbance. However, the length of endoscopy experience and the ratio of endoscopists to nurses were not adequate to establish an effective predictive model for endoscopy complications. CONCLUSION The workload and job satisfaction of endoscopists are valuable predictors for medical malpractice or patient disturbance. More comprehensive data are needed to establish quality-predictive models for endoscopic complications.
- 3 September 2018
- Published by S. Karger AG in Cardiology
- Vol. 140 (4) , 239-246
Association between Radiotherapy and Anatomic Severity of Coronary Artery Disease: A Propensity Score Matching Comparison Among Adult-Onset Thoracic Cancer Survivors
Objective: To investigate the association between radiotherapy and anatomic severity of coronary artery disease (CAD) using the SYNTAX scores (SXscores) of coronary angiograms in adult-onset thoracic cancer survivors. Methods: A total of 152 patients who previously had thoracic cancer and underwent coronary angiography between 2010 and 2016 were examined. Propensity score matching (PSM) was used to identify 27 well-matched pairs of patients. Characteristics and coronary angiograms were collected from each patient. Coronary artery abnormalities were assessed using SXscores of coronary angiograms. Results: Among the 152 patients, the SXscores and percentage of high SXscores were higher in the radiotherapy group than in the non-radiotherapy group; however, the latter was not significantly different (p = 0.0266 and p = 0.064, respectively). After PSM, the SXscores and percentage of high SXscores were significantly higher in the radiotherapy group than in the non-radiotherapy group (22 [interquartile range (IQR) 10.00–30.00] vs. 15.00 [IQR 4.00–26.00], p = 0.0459), (70.07 vs. 44.44%, p = 0.027), respectively. After adjusting for related risk factors and chemotherapy, the OR of radiotherapy for a high SXscore was 3.674 (95% CI 1.094–12.343) by logistic regression analysis. Conclusion: Thoracic cancer survivors who underwent radiotherapy have higher SXscores and are at a higher risk of developing anatomically severe CAD, independent of chemotherapy.
- 3 September 2018
- Published by S. Karger AG in Cardiology
- Vol. 140 (4) , 239-246
Association between Radiotherapy and Anatomic Severity of Coronary Artery Disease: A Propensity Score Matching Comparison Among Adult-Onset Thoracic Cancer Survivors
Objective: To investigate the association between radiotherapy and anatomic severity of coronary artery disease (CAD) using the SYNTAX scores (SXscores) of coronary angiograms in adult-onset thoracic cancer survivors. Methods: A total of 152 patients who previously had thoracic cancer and underwent coronary angiography between 2010 and 2016 were examined. Propensity score matching (PSM) was used to identify 27 well-matched pairs of patients. Characteristics and coronary angiograms were collected from each patient. Coronary artery abnormalities were assessed using SXscores of coronary angiograms. Results: Among the 152 patients, the SXscores and percentage of high SXscores were higher in the radiotherapy group than in the non-radiotherapy group; however, the latter was not significantly different (p = 0.0266 and p = 0.064, respectively). After PSM, the SXscores and percentage of high SXscores were significantly higher in the radiotherapy group than in the non-radiotherapy group (22 [interquartile range (IQR) 10.00–30.00] vs. 15.00 [IQR 4.00–26.00], p = 0.0459), (70.07 vs. 44.44%, p = 0.027), respectively. After adjusting for related risk factors and chemotherapy, the OR of radiotherapy for a high SXscore was 3.674 (95% CI 1.094–12.343) by logistic regression analysis. Conclusion: Thoracic cancer survivors who underwent radiotherapy have higher SXscores and are at a higher risk of developing anatomically severe CAD, independent of chemotherapy.